福萊特(601865.SH)2022年度淨利潤21.23億元、同比增長0.13%
格隆匯3月27日丨福萊特(601865.SH)發佈2022年年度報吿,實現營業收入154.61億元,同比增長77.44%;歸屬於上市公司股東的淨利潤21.23億元,同比增長0.13%;歸屬於上市公司股東的扣除非經常性損益的淨利潤20.75億元,同比增長0.94%;基本每股收益0.99元。
經綜合考慮公司實際經營情況、在建項目自有資金需求及非公開發行A股股票事宜等因素,為實現公司穩定持續的發展,創造更大的業績回報股東,更好的維護公司及全體股東的長遠利益,公司2022年度擬不進行利潤分配,也不以資本公積金轉增股本。本次未分配利潤將用於公司在建項目自有資金投入需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.